Clinical trials: Esophagogastric Junction
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
The goal of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and anti-tumor activities of cadonilimab in combination with Ivonescimab plus chemotherapy as first-line therapy in adult…
- Trial name
- NCT06196697
- Testing
- Cadonilimab, Ivonescimab, XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Harbin Medical University
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
- Trial name
- NCT00098527
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy…
- Trial name
- NCT05671822
- Testing
- SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Esophagogastric Junction Adenocarcinoma, Siewert Type II Adenocarcinoma of Esophagogastric Junction
A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG
Objective: To evaluate the safety, feasibility and clinical efficacy of transthoracic single-hole assisted laparoscopic radical gastrectomy for Siewert Type Ⅱ adenocarcinoma of esophagogastric junction.
- Trial name
- NCT04423354
- Testing
- Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Gastric Cancer (GC), Gastroesophageal Junction Cancer
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
The goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or…
- Conditions
- Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer
- Trial name
- NCT07315854
- Testing
- Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Beijing Friendship Hospital
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
This study examines whether adding the drug Zolbetuximab to an existing treatment (Paclitaxel and Ramucirumab) can improve patients' survival.
- Trial name
- RAINSPOT (NCT06962137)
- Testing
- zolbetuximab, Retrospective cohort, no intervention
- Where
- 6 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Stomach Neoplasms
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
This was a single-arm, prospective study to investigate the efficacy and safety of fruquintinib combined with sintilimab in the second-line treatment of Chinese patients with advanced gastric/GEJ adenocarcinoma.
- Trial name
- NCT05625737
- Testing
- Fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Adenocarcinoma
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
This study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced…
- Trial name
- NCT07464756
- Testing
- SHR-1701, apatinib, S-1 & Oxaliplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Epiphora Due to Insufficient Drainage, Left Side, Epiphora Due to Insufficient Drainage, Right Side
Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis
On the basis of minimally invasive Ivor Lewis operation for the treatment of lower thoracic esophageal cancer or esophageal gastric junction cancer, the purpose of this study is to compare the probability of anastomotic leakage…
- Trial name
- NCT05812495
- Testing
- Esophagogastric Side to Side Anastomosis, Esophagogastric End to Side Anastomosis
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
This is a multicenter, open-label, single-arm phase II study evaluating the efficacy and safety of mannatide in combination with CAPOX chemotherapy and tislelizumab as first-line treatment for patients with recurrent or…
- Trial name
- NCT07655661
- Testing
- Oxaliplatin, Capecitabine, Tislelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Ming Liu
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
- Trial name
- ILIAD (NCT03735290)
- Testing
- ilixadencel, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mendus
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
- Trial name
- NCT06947291
- Testing
- Glumetinib Tablets, Docetaxel for Injection (Albumin-bound)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Esophageal Cancer, Gastric Cancer
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer.
- Trial name
- NCT02283359
- Testing
- Selinexor, Irinotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
Open label, randomised, multicenter, superiority study for efficacy. Patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction without gross or microscopic evidence of residual disease after…
- Trial name
- ITACA-S (NCT01640782)
- Testing
- Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin, Leucovorin, 5-Fluorouracil
- Where
- 101 sites in Italy
- Volunteers
- 1,100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Gastroesophageal Reflux Disease
Antireflux Ablation Therapy (ARAT) Vs Antireflux Mucosectomy (ARMS) In The Management Of Gastroesophageal Reflux Disease
Gastroesophageal reflux disease has a high global prevalence, proton pump inhibitors are the cornerstone in the management but 10-20% of the patients are refractory to these, surgical treatment being an option of treatment in…
- Trial name
- NCT04036942
- Testing
- Ablation of the gastroesophageal junction with hybrid argon plasma, mucosectomy with band of the gastroesophageal junction
- Where
- Mexico
- Sponsor
- Coordinación de Investigación en Salud, Mexico